Boston Scientific has announced US Food Administration (FDA) clearance of the AVVIGO+ multi-modality guidance system, a next-generation intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system.
The system features advanced software and hardware features designed to provide high-quality IVUS vessel imaging and physiology experience during percutaneous coronary intervention (PCI) procedures, the company said in a statement.
Building upon the AVVIGO Guidance System II, the technology helps to inform treatment decisions and enable faster, more efficient treatment procedures such as angioplasties and atherectomies for patients with coronary artery disease, Boston Scientific adds. The company also recently received CE mark, with launch anticipated early next year.
“We are pleased to introduce US clinicians to the next-generation AVVIGO+ Multi-Modality Guidance System, which builds upon the AVVIGO guidance system II and provides fast, intuitive and accurate vessel and lesion assessment capabilities for percutaneous coronary interventions,” said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific. “Coming on the heels of the updated American College of Cardiology (ACC) guidelines recommending intracoronary imaging during PCIs, we believe this enhanced and automated tool will help physicians optimise these procedures to provide better outcomes for their patients with coronary artery disease.”